vs
Apellis Pharmaceuticals, Inc.（APLS）与Heritage Insurance Holdings, Inc.（HRTG）财务数据对比。点击上方公司名可切换其他公司
Heritage Insurance Holdings, Inc.的季度营收约是Apellis Pharmaceuticals, Inc.的1.1倍（$215.3M vs $199.9M），Heritage Insurance Holdings, Inc.净利率更高（31.0% vs -29.5%，领先60.5%），Heritage Insurance Holdings, Inc.同比增速更快（2.4% vs -5.9%），Heritage Insurance Holdings, Inc.自由现金流更多（$174.2M vs $-14.3M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs 6.1%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
该公司是一家位于美国佛罗里达州的财产意外保险公司，在美国多个沿海州开展业务，主要为客户提供商业保险、住宅保险、房主保险以及洪水保险等各类财产意外保障产品。
APLS vs HRTG — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $215.3M |
| 净利润 | $-59.0M | $66.7M |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | 41.6% |
| 净利率 | -29.5% | 31.0% |
| 营收同比 | -5.9% | 2.4% |
| 净利润同比 | -62.2% | 228.6% |
| 每股收益（稀释后） | $-0.40 | $2.15 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $199.9M | $215.3M | ||
| Q3 25 | $458.6M | $212.5M | ||
| Q2 25 | $178.5M | $208.0M | ||
| Q1 25 | $166.8M | $211.5M | ||
| Q4 24 | $212.5M | $210.3M | ||
| Q3 24 | $196.8M | $211.8M | ||
| Q2 24 | $199.7M | $203.6M | ||
| Q1 24 | $172.3M | $191.3M |
| Q4 25 | $-59.0M | $66.7M | ||
| Q3 25 | $215.7M | $50.4M | ||
| Q2 25 | $-42.2M | $48.0M | ||
| Q1 25 | $-92.2M | $30.5M | ||
| Q4 24 | $-36.4M | $20.3M | ||
| Q3 24 | $-57.4M | $8.2M | ||
| Q2 24 | $-37.7M | $18.9M | ||
| Q1 24 | $-66.4M | $14.2M |
| Q4 25 | -25.6% | 41.6% | ||
| Q3 25 | 48.7% | 33.0% | ||
| Q2 25 | -18.6% | 31.2% | ||
| Q1 25 | -50.0% | 20.1% | ||
| Q4 24 | -12.3% | 15.0% | ||
| Q3 24 | -24.0% | 5.5% | ||
| Q2 24 | -14.7% | 13.6% | ||
| Q1 24 | -36.0% | 11.9% |
| Q4 25 | -29.5% | 31.0% | ||
| Q3 25 | 47.0% | 23.7% | ||
| Q2 25 | -23.6% | 23.1% | ||
| Q1 25 | -55.3% | 14.4% | ||
| Q4 24 | -17.1% | 9.7% | ||
| Q3 24 | -29.2% | 3.8% | ||
| Q2 24 | -18.9% | 9.3% | ||
| Q1 24 | -38.5% | 7.4% |
| Q4 25 | $-0.40 | $2.15 | ||
| Q3 25 | $1.67 | $1.63 | ||
| Q2 25 | $-0.33 | $1.55 | ||
| Q1 25 | $-0.74 | $0.99 | ||
| Q4 24 | $-0.30 | $0.66 | ||
| Q3 24 | $-0.46 | $0.27 | ||
| Q2 24 | $-0.30 | $0.61 | ||
| Q1 24 | $-0.54 | $0.47 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $559.3M |
| 总债务越低越好 | — | $78.4M |
| 股东权益账面价值 | $370.1M | $505.3M |
| 总资产 | $1.1B | $2.2B |
| 负债/权益比越低杠杆越低 | — | 0.16× |
8季度趋势，按日历期对齐
| Q4 25 | $466.2M | $559.3M | ||
| Q3 25 | $479.2M | $560.4M | ||
| Q2 25 | $370.0M | $473.5M | ||
| Q1 25 | $358.4M | $425.9M | ||
| Q4 24 | $411.3M | $452.7M | ||
| Q3 24 | $396.9M | $509.9M | ||
| Q2 24 | $360.1M | $480.9M | ||
| Q1 24 | $325.9M | $386.1M |
| Q4 25 | — | $78.4M | ||
| Q3 25 | — | $79.3M | ||
| Q2 25 | — | $92.4M | ||
| Q1 25 | — | $94.8M | ||
| Q4 24 | — | $116.3M | ||
| Q3 24 | — | $118.6M | ||
| Q2 24 | — | $120.8M | ||
| Q1 24 | $93.1M | $123.0M |
| Q4 25 | $370.1M | $505.3M | ||
| Q3 25 | $401.2M | $437.3M | ||
| Q2 25 | $156.3M | $383.3M | ||
| Q1 25 | $164.2M | $329.0M | ||
| Q4 24 | $228.5M | $290.8M | ||
| Q3 24 | $237.1M | $279.3M | ||
| Q2 24 | $264.3M | $255.3M | ||
| Q1 24 | $266.7M | $234.9M |
| Q4 25 | $1.1B | $2.2B | ||
| Q3 25 | $1.1B | $2.4B | ||
| Q2 25 | $821.4M | $2.5B | ||
| Q1 25 | $807.3M | $2.2B | ||
| Q4 24 | $885.1M | $2.5B | ||
| Q3 24 | $901.9M | $2.4B | ||
| Q2 24 | $904.5M | $2.6B | ||
| Q1 24 | $831.9M | $2.1B |
| Q4 25 | — | 0.16× | ||
| Q3 25 | — | 0.18× | ||
| Q2 25 | — | 0.24× | ||
| Q1 25 | — | 0.29× | ||
| Q4 24 | — | 0.40× | ||
| Q3 24 | — | 0.42× | ||
| Q2 24 | — | 0.47× | ||
| Q1 24 | 0.35× | 0.52× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $182.2M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $174.2M |
| 自由现金流率自由现金流/营收 | -7.1% | 80.9% |
| 资本支出强度资本支出/营收 | 0.1% | 3.7% |
| 现金转化率经营现金流/净利润 | — | 2.73× |
| 过去12个月自由现金流最近4个季度 | $45.0M | $337.4M |
8季度趋势，按日历期对齐
| Q4 25 | $-14.2M | $182.2M | ||
| Q3 25 | $108.5M | $124.3M | ||
| Q2 25 | $4.4M | $43.3M | ||
| Q1 25 | $-53.4M | $837.0K | ||
| Q4 24 | $19.4M | $87.1M | ||
| Q3 24 | $34.1M | $-13.4M | ||
| Q2 24 | $-8.3M | $152.2M | ||
| Q1 24 | $-133.0M | $4.3M |
| Q4 25 | $-14.3M | $174.2M | ||
| Q3 25 | $108.3M | $122.7M | ||
| Q2 25 | $4.4M | $41.8M | ||
| Q1 25 | $-53.4M | $-1.3M | ||
| Q4 24 | $19.3M | $78.9M | ||
| Q3 24 | — | $-16.3M | ||
| Q2 24 | $-8.4M | $149.8M | ||
| Q1 24 | $-133.3M | $4.1M |
| Q4 25 | -7.1% | 80.9% | ||
| Q3 25 | 23.6% | 57.8% | ||
| Q2 25 | 2.5% | 20.1% | ||
| Q1 25 | -32.0% | -0.6% | ||
| Q4 24 | 9.1% | 37.5% | ||
| Q3 24 | — | -7.7% | ||
| Q2 24 | -4.2% | 73.6% | ||
| Q1 24 | -77.3% | 2.1% |
| Q4 25 | 0.1% | 3.7% | ||
| Q3 25 | 0.0% | 0.7% | ||
| Q2 25 | 0.0% | 0.7% | ||
| Q1 25 | 0.0% | 1.0% | ||
| Q4 24 | 0.0% | 3.9% | ||
| Q3 24 | 0.0% | 1.4% | ||
| Q2 24 | 0.0% | 1.2% | ||
| Q1 24 | 0.2% | 0.1% |
| Q4 25 | — | 2.73× | ||
| Q3 25 | 0.50× | 2.47× | ||
| Q2 25 | — | 0.90× | ||
| Q1 25 | — | 0.03× | ||
| Q4 24 | — | 4.29× | ||
| Q3 24 | — | -1.64× | ||
| Q2 24 | — | 8.07× | ||
| Q1 24 | — | 0.30× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
HRTG
暂无分部数据
